Boston Scientific Corp (BSX): who owns it and who trades it
As of Nov 16, 2026, BSX insiders reported 3 open-market sales worth $16.8M and 10 purchases worth $10M in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Michael F Mahoney (CEO), with $15M. 8 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Boston Scientific
From the latest filingsOverall: about as much buying as selling. Famous investors and Congress mostly sold. Insiders mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BSX
1,473 funds and institutions reported BSX shares worth $60.1B at the end of Q2 2026, about 97% of the company. The largest holder is BlackRock, Inc. with 8.7%.
Funds and institutions (13F) 97%Everyone else 3%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 129.68M | 8.72% | $5.5B | -2% |
| Vanguard Capital Management LLC | 97.09M | 6.53% | $4.1B | +1% |
| California State Teachers Retirement System | 96.91M | 6.52% | $2.3B | +4114% |
| State Street Corp | 70.11M | 4.72% | $3B | +3% |
| Primecap Management Co | 50.52M | 3.40% | $2.2B | +55% |
| FMR LLC (Fidelity) | 45.70M | 3.07% | $2B | -38% |
| Geode Capital Management, LLC | 33.44M | 2.25% | $1.4B | +0% |
| Vanguard Portfolio Management LLC | 29.79M | 2.00% | $1.3B | No change |
| D. E. Shaw & Co., Inc. | 25.46M | 1.71% | $1.1B | +5% |
| Massachusetts Financial Services Co | 24.86M | 1.67% | $1.5B | +126% |
| JPMorgan Chase & Co | 23.91M | 1.61% | $1B | – |
| Arrowstreet Capital, Limited Partnership | 23.29M | 1.57% | $994M | +68% |
| Norges Bank | 21.17M | 1.42% | $904M | – |
| Two Sigma Investments, LP | 19.36M | 1.30% | $826M | +106% |
| Morgan Stanley | 18.95M | 1.27% | $809M | -15% |
| Jupiter Topco LLC | 18.82M | 1.27% | $803M | – |
| Bollard Group LLC | 18.42M | 1.24% | $786M | -1% |
| Goldman Sachs Group Inc | 16.95M | 1.14% | $724M | -10% |
| Capital World Investors | 16.81M | 1.13% | $718M | +10% |
| UBS Group AG | 16.35M | 1.10% | $698M | +10% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BSX insiders reported $10M of open-market purchases and $16.8M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Susan E Morano | Director | Purchase | 2,040 | $49.22 | $100K | Form 4 |
| Aug 5, 2026 | David C Habiger | Director | Purchase | 2,100 | $47.59 | $99.9K | Form 4 |
| Aug 4, 2026 | David C Habiger | Director | Purchase | 140 | $48.59 | $6.8K | Form 4 |
| Aug 3, 2026 | David C Habiger | Director | Purchase | 1,042 | $48.07 | $50.1K | Form 4 |
| Aug 3, 2026 | Michael F Mahoney | CEO | Purchase | 186,240 | $48.33 | $9M | Form 4 |
| Jul 31, 2026 | Edward J Ludwig | Director | Purchase | 5,000 | $45.48 | $227K | Form 4 |
| May 20, 2026 | Cheryl Pegus | Director | Purchase | 1,770 | $56.49 | $100K | Form 4 |
| May 20, 2026 | Edward J Ludwig | Director | Purchase | 3,580 | $56.68 | $203K | Form 4 |
| May 20, 2026 | David C Habiger | Director | Purchase | 2,250 | $55.92 | $126K | Form 4 |
| May 19, 2026 | David C Habiger | Director | Purchase | 2,200 | $56.95 | $125K | Form 4 |
| Feb 2, 2026 | Michael F Mahoney | CEO | Sale plan | 159,701 | $93.49 | $14.9M | Form 4 |
| Feb 2, 2026 | Michael F Mahoney | CEO | Sale plan | 1,200 | $94.06 | $113K | Form 4 |
| Dec 1, 2025 | Arthur C Butcher | Vice president | Sale plan | 17,313 | $101.55 | $1.8M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Michael F Mahoney | Chairman, President & CEO, Director | $9M | $15M | Aug 3, 2026 |
| Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | – | $1.8M | Dec 1, 2025 |
| Edward J Ludwig | Director | $430K | – | Jul 31, 2026 |
| David C Habiger | Director | $408K | – | Aug 5, 2026 |
| Susan E Morano | Director | $100K | – | Aug 25, 2026 |
| Cheryl Pegus | Director | $100K | – | May 20, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BSX short interest
Low short interest. 2.4% of BSX shares are sold short: about 1 share in 41. Over the last 12 reports the number of shares short went up 12%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 35.11M BSX shares were sold short, 2.4% of the shares outstanding, down 13.7% from the report before. At the average daily volume of 21.26M shares, buying them all back would take about 1.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 35.11M | 2.42% | -14% | 21.26M | 1.6 |
| Oct 15, 2026 | 40.71M | 2.81% | -2% | 15.74M | 2.6 |
| Sep 30, 2026 | 41.41M | 2.86% | -11% | 21.98M | 1.9 |
| Sep 15, 2026 | 46.50M | 3.21% | -3% | 19.75M | 2.4 |
| Aug 31, 2026 | 48.17M | 3.32% | +74% | 21.04M | 2.3 |
| Aug 14, 2026 | 27.62M | 1.91% | +24% | 17.64M | 1.6 |
| Jul 31, 2026 | 22.28M | 1.54% | -21% | 21.97M | 1.0 |
| Jul 15, 2026 | 28.28M | 1.90% | +1% | 16.78M | 1.7 |
| Jun 30, 2026 | 27.94M | 1.88% | -6% | 23.40M | 1.2 |
| Jun 15, 2026 | 29.75M | 2.00% | -48% | 20.62M | 1.4 |
| May 29, 2026 | 57.49M | 3.87% | +83% | 25.51M | 2.2 |
| May 15, 2026 | 31.42M | 2.11% | +10% | 17.71M | 1.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded BSX
Since Nov 17, 2024, 8 members of Congress reported 14 purchases and 22 sales of BSX. The latest was a sale by Kevin Hern on Sep 9, 2026, reported Sep 25, 2026.
Purchases 14Sales 22
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Kevin Hern (R-OK) | Sale | $50K–$100K | Joint | Sep 25, 2026 | Report |
| Sep 4, 2026 | Kevin Hern (R-OK) | Partial sale | $50K–$100K | Joint | Sep 25, 2026 | Report |
| Sep 3, 2026 | Kevin Hern (R-OK) | Sale | $1K–$15K | Child | Sep 25, 2026 | Report |
| Aug 31, 2026 | Kevin Hern (R-OK) | Sale | $15K–$50K | Joint | Sep 25, 2026 | Report |
| Aug 18, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 10, 2026 | Report |
| Jun 5, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jul 2, 2026 | Report |
| Jun 5, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Jul 2, 2026 | Report |
| Jun 4, 2026 | John Boozman (R-AR) | Partial sale | $1K–$15K | Joint | Jul 13, 2026 | Report |
| May 29, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jun 8, 2026 | Report |
| May 19, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jun 8, 2026 | Report |
| May 11, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jun 8, 2026 | Report |
| Mar 27, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
| Feb 10, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Mar 9, 2026 | Report |
| Jan 30, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Feb 13, 2026 | Report |
| Dec 24, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Jan 12, 2026 | Report |
| Dec 17, 2025 | John Boozman (R-AR) | Partial sale | $1K–$15K | Joint | Jan 13, 2026 | Report |
| Nov 18, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Dec 15, 2025 | Report |
| Oct 31, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 28, 2025 | Kevin Hern (R-OK) | Partial sale | $15K–$50K | Joint | Nov 16, 2025 | Report |
| Oct 17, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Nov 18, 2025 | Report |
| Sep 23, 2025 | Val T. Hoyle (D-OR) | Sale | $1K–$15K | Spouse | Oct 10, 2025 | Report |
| Aug 4, 2025 | Lisa C. McClain (R-MI) | Partial sale | $1K–$15K | Spouse | Sep 12, 2025 | Report |
| Jul 31, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Aug 14, 2025 | Report |
| Jun 26, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Jul 10, 2025 | Report |
| Jun 11, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Jul 10, 2025 | Report |
| May 13, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Jun 6, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | Jun 22, 2025 | Report |
| Apr 28, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | May 6, 2025 | Report |
| Apr 21, 2025 | Bruce Westerman (R-AR) | Sale | $1K–$15K | Self | May 12, 2025 | Report |
| Mar 17, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Apr 7, 2025 | Report |
| Mar 3, 2025 | Bruce Westerman (R-AR) | Purchase | $1K–$15K | Self | Apr 16, 2025 | Report |
| Feb 24, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Mar 6, 2025 | Report |
| Feb 13, 2025 | John Boozman (R-AR) | Purchase | $1K–$15K | Joint | Mar 6, 2025 | Report |
| Dec 11, 2024 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Boston Scientific company events
Boston Scientific filed 19 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership, cyberattack, job cuts). The latest was on Oct 28, 2026.
- Oct 28, 2026ResultsReleased financial results. Filing
- Oct 7, 2026LeadershipBoston Scientific Corporation announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027. Filing
- Sep 23, 2026LeadershipArthur C. Butcher informed Boston Scientific Corporation that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027. Filing
- Sep 8, 2026CyberattackAs previously disclosed in a Current Report on Form 8-K filed on August 26, 2026 with the Securities and Exchange Commission, on August 25, 2026, Boston Scientific Corporation identified a cybersecurity incident that affected certain of its information technology systems and resulted in a global… Filing
- Aug 26, 2026AnnouncementBoston Scientific Corporation identified a cybersecurity incident affecting certain of its information technology systems that has resulted in a global disruption to the Company’s operations. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- Jul 27, 2026Job cutsAnnounced job cuts or other exit costs. Filing
- May 18, 2026AnnouncementBoston Scientific Corporation issued a press release announcing that the Company has entered into an accelerated share repurchase agreement with JPMorgan Chase Bank, National Association for $2 billion of its common stock, as part of its previously announced $5 billion share repurchase authorization. Filing
- May 18, 2026AnnouncementBoston Scientific Corporation issued a press release announcing that the Company has entered into an investment agreement with MiRus LLC, a privately held company developing and commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of cardiovascular and… Filing
- May 5, 2026VoteReported shareholder vote results. Filing
- Apr 22, 2026ResultsReleased financial results. Filing
- Mar 30, 2026AnnouncementBoston Scientific Corporation issued a press release announcing results from the Company's HI-PEITHO clinical trial. Filing
- Feb 26, 2026AgreementBoston Scientific Corporation entered into a $3.000 billion revolving credit agreement by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. Filing
- Feb 23, 2026LeadershipOn February 18, 2026 the Board of Directors of Boston Scientific Corporation, upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber… Filing
- Feb 5, 2026LeadershipYoshiaki Fujimori informed Boston Scientific Corporation that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders. Filing
- Feb 4, 2026ResultsReleased financial results. Filing
- Jan 15, 2026AgreementBoston Scientific Corporation, a Delaware corporation, entered into an Agreement and Plan of Merger with Pinehurst Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company, and Penumbra, Inc., a Delaware corporation, providing for the merger of Merger Sub with and into… Filing
- Jan 15, 2026AnnouncementShared information with investors. Filing
- Nov 19, 2025LeadershipUpon the recommendation of the Executive Compensation and Human Resources Committee, the Board of Directors of Boston Scientific Corporation approved the Company’s 2026 Annual Bonus Plan effective for the performance year of January 1, 2026 through December 31, 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Boston Scientific financials
Famous investors that hold BSX
8 of the 50 well-known investors we track reported holding BSX in their latest 13F filing. The largest position is Ken Griffin's, worth $341M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 7.81M | $341M | 0.2% | +57% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.77M | $77.1M | 0.1% | -27% |
| Israel Englander · Millennium Management | Q3 2026 | 1.12M | $27.1M | 0.0% | -79% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 437,208 | $19.1M | 0.1% | -1% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 292,236 | $12.8M | 0.0% | -12% |
| Larry Robbins · Glenview Capital Management | Q3 2026 | 70,348 | $3.1M | 0.1% | -38% |
| Jeremy Grantham · GMO | Q3 2026 | 28,600 | $1.2M | 0.0% | +31% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 5,101 | $223K | 0.0% | -100% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Boston Scientific Corp (BSX) stock
Who owns the most BSX stock?
The largest reported owner of Boston Scientific Corp (BSX) is BlackRock, Inc., with 8.7% of the company. In total, 1,473 funds and institutions reported holding BSX at the end of Q2 2026, together about 97% of the shares. See the largest owners.
Are BSX insiders buying or selling?
In the last 12 months, BSX insiders reported 10 open-market purchases worth $10M and 3 sales worth $16.8M. The latest trade was on Aug 25, 2026. See every trade.
What is the short interest in BSX?
As of Oct 30, 2026, 35.11M BSX shares were sold short, 2.4% of the shares outstanding, down 13.7% from the report before. At the average daily volume of 21.26M shares, buying them all back would take about 1.6 trading days (days to cover). See the history.
Have members of Congress traded BSX?
Yes. 8 members of Congress reported 14 purchases and 22 sales of BSX since Nov 17, 2024. The latest was reported on Sep 25, 2026. See the trades.
Which famous investors hold BSX?
8 of the 50 well-known investors we track reported BSX in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $341M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.